Key points are not available for this paper at this time.
May support extended apixaban in select VTE patients; leaves open optimal duration and subgroups.
Agnelli, Giancarlo*; Buller, Harry R.†; Cohen, Alexander‡; Curto, Madelyn§; Gallus, Alexander S.∥; Johnson, Margot§; Porcari, Anthony§; Raskob, Gary E.¶; Weitz, Jeffrey I.# For the Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis With First-Line Therapy-Extended Treatment (AMPLIFY-EXT) Investigators Author Information
No takes yet. Share an insight, caveat, or question.
Agnelli et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: